Where Will Tarsus Pharmaceuticals Inc (TARS) Stock Go Next After It Has Risen 11.45% in a Week?

Tarsus Pharmaceuticals Inc (TARS) stock has gained 11.45% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Tarsus Pharmaceuticals Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on TARS!

See Full TARS Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With TARS Stock Today?

Tarsus Pharmaceuticals Inc (TARS) stock has risen 1.17% while the S&P 500 is down -0.57% as of 12:00 PM on Thursday, Oct 5. TARS is up $0.21 from the previous closing price of $17.89 on volume of 62,364 shares. Over the past year the S&P 500 has gained 11.83% while TARS is up 1.46%. TARS lost -$3.40 per share in the over the last 12 months.

More About Tarsus Pharmaceuticals Inc

Tarsus Pharmaceuticals Inc is a late clinical-stage biopharmaceutical company. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's lead candidate TP-03, is a novel drug that targets the Demodex mite nervous system to kill the mites. Click Here to get the full Stock Report for Tarsus Pharmaceuticals Inc stock.